M. Maxwell

发表

SIRT 2-and NRF 2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington ’ s Disease Models Highlights

R. Abagyan, J. Marsh, J. Landers, 2016 .

SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis

Christian Neri, Emmanuel Lambert, Leslie M. Thompson, 2010, Proceedings of the National Academy of Sciences.

Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease

Ruben Abagyan, Irina Kufareva, Bradley T. Hyman, 2007, Science.

Biological and Potential Therapeutic Roles of Sirtuin Deacetylases

A. Kazantsev, R. Luthi-Carter, D. Taylor, 2008, Cellular and Molecular Life Sciences.

RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells.

Robert H. Brown, A. Kazantsev, P. Pasinelli, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.

R. Abagyan, A. Young, B. Hyman, 2007, Science.

The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS.

Elizabeth M. Tomkinson, S. Hersch, A. Kazantsev, 2011, Human molecular genetics.

M. M. Maxwell, N. Aziz, J. Nearing, 1995, The Journal of Biological Chemistry.

Ke 6 Gene SEQUENCE AND ORGANIZATION AND ABERRANT REGULATION IN MURINE POLYCYSTIC KIDNEY DISEASE*

N. Aziz, J. Nearing, M. Maxwell, 1995 .

A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.

A. Young, D. Housman, E. Wanker, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Two Approaches to Drug Discovery in SOD1-Mediated ALS

Robert H. Brown, M. Glicksman, A. Kazantsev, 2006, Journal of biomolecular screening.

Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation

C. Jamieson, C. Magyar, Guney Boso, 2010, Neuromuscular Disorders.

Downregulation of Ke 6, a novel gene encoded within the major histocompatibility complex, in murine polycystic kidney disease

B. Brenner, M. M. Maxwell, N. Aziz, 1993, Molecular and cellular biology.

Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases.

A. Young, B. Hyman, D. Housman, 2006, Proceedings of the National Academy of Sciences of the United States of America.

New VAPB deletion variant and exclusion of VAPB mutations in familial ALS

A. Al-Chalabi, C. Shaw, J. Glass, 2008, Neurology.

SIRT2- and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington's Disease Models

R. Abagyan, J. Marsh, J. Landers, 2016 .

Evaluation of Histone Deacetylases as Drug Targets in Huntington’s Disease models

S. Hersch, L. Altucci, A. Mai, 2010, PLoS currents.

Discovery of a Novel Small-Molecule Targeting Selective Clearance of Mutant Huntingtin Fragments

A. Young, D. Housman, Z. Hollingsworth, 2007, Journal of biomolecular screening.

SIRT2- and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington's Disease Models.

R. Abagyan, J. Marsh, J. Landers, 2016, Cell chemical biology.

A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase.

G. Bates, David M. Taylor, B. Woodman, 2011, ACS chemical biology.

Discovery of bioactive small-molecule inhibitor of poly adp-ribose polymerase: implications for energy-deficient cells.

R. Abagyan, M. MacDonald, A. Young, 2006, Chemistry & biology.

accumulates in the aging CNS

Elizabeth M. Tomkinson, S. Hersch, L. Quinti, 2011 .

A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.

A. Young, D. Housman, E. Wanker, 2005, Proceedings of the National Academy of Sciences of the United States of America.